oncodaily - Immune checkpoint blockade (ICB) benefits only a subset of patients with head and neck squamous cell carcinoma (HNSCC), and commonly used biomarkers (PD-L1, TMB) remain imperfect in this setting. This […]
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Saturday, January 3, 2026, 11:20 am / permalink 17458 / 7 stories in 2 months
Judge orders Leapfrog to remove safety grades for five Florida hospitals (21 hrs)
Daily multivitamin slows epigenetic aging in randomized COSMOS analysis (40 hrs)
White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.